Bristol Myers Squibb Receives FDA Approval for Opdivo in Adjuvant Esophageal Cancer

Bristol Myers Squibb today announced that the FDA has approved Opdivo (nivolumab) as adjuvant treatment for adults with esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease following neoadjuvant chemoradiotherapy and resection. In the Phase 3 CheckMate-577 trial, Opdivo demonstrated a statistically significant improvement in disease-free survival compared to placebo. The median DFS was 22.4 months for Opdivo versus 11.0 months for placebo. This approval provides patients with residual disease after neoadjuvant chemoradiotherapy a new adjuvant immunotherapy option.